Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12255
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huang, Gene Khai Lin | - |
dc.contributor.author | Johnson, Paul D R | - |
dc.date.accessioned | 2015-05-16T01:54:54Z | |
dc.date.available | 2015-05-16T01:54:54Z | |
dc.date.issued | 2014-07-01 | - |
dc.identifier.citation | Expert Review of Anti-infective Therapy; 12(7): 855-65 | en_US |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12255 | en |
dc.description.abstract | Buruli ulcer (Mycobacterium ulcerans infection) is a neglected tropical disease of skin and subcutaneous tissue that can result in long-term cosmetic and functional disability. It is a geographically restricted infection but transmission has been reported in endemic areas in more than 30 countries worldwide. The heaviest burden of disease lies in West and Sub-Saharan Africa where it affects children and adults in subsistence agricultural communities. Mycobacterium ulcerans infection is probably acquired via inoculation of the skin either directly from the environment or indirectly via insect bites. The environmental reservoir and exact route of transmission are not completely understood. It may be that the mode of acquisition varies in different parts of the world. Because of this uncertainty it has been nicknamed the 'mysterious disease'. The therapeutic approach has evolved in the past decade from aggressive surgical resection alone, to a greater focus on antibiotic therapy combined with adjunctive surgery. | en_US |
dc.language.iso | en | en |
dc.subject.other | Buruli ulcer | en |
dc.subject.other | Insertion sequence IS2404 | en |
dc.subject.other | Mycobacterium ulcerans | en |
dc.subject.other | WHO neglected tropical disease | en |
dc.subject.other | clarithromycin | en |
dc.subject.other | fluroquinolones | en |
dc.subject.other | mycolactone | en |
dc.subject.other | paradoxical reaction | en |
dc.subject.other | rifampicin | en |
dc.subject.other | streptomycin | en |
dc.subject.other | Animals | en |
dc.subject.other | Anti-Bacterial Agents.adverse effects.therapeutic use | en |
dc.subject.other | Buruli Ulcer.epidemiology.pathology.therapy.transmission | en |
dc.subject.other | Disease Reservoirs.microbiology | en |
dc.subject.other | Humans | en |
dc.subject.other | Neglected Diseases.epidemiology.microbiology.pathology.therapy | en |
dc.subject.other | Prevalence | en |
dc.subject.other | Zoonoses.epidemiology.pathology.therapy.transmission | en |
dc.title | Epidemiology and management of Buruli ulcer. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Expert Review of Anti-infective Therapy | en_US |
dc.identifier.affiliation | Infectious | en_US |
dc.identifier.doi | 10.1586/14787210.2014.910113 | en_US |
dc.description.pages | 855-65 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24918117 | en |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en |
local.name.researcher | Johnson, Paul D R | |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Infectious Diseases | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.